Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Baxter reports positive real-world study data for Advate

Baxter reports positive real-world study data for Advate

3rd July 2013

Baxter has presented two comprehensive analyses that demonstrate the strong performance of its haemophilia therapy Advate in both real-world and clinical settings.

A meta-analysis of post-authorisation safety studies of the drug that involved 1,200 haemophilia A patients across 15 countries confirmed Advate's safety and effectiveness profile, as well as its low rate of inhibitor development.

Meanwhile, a database of more than ten years of Advate clinical data from 12 interventional studies backed up its previously-demonstrated safety and tolerability in children and adults in a wide variety of clinical settings, with no new safety signals being recorded.

Dr Bruce Ewenstein, vice-president of clinical affairs for Baxter, said: "This meta-analysis of the post-market surveillance database … demonstrates a global patient experience with Advate that is consistent with the results reported in our highly controlled clinical programmes."

Earlier this year, the company supported World Haemophilia Day by making educational materials available online for patients, while also outlining its ongoing commitment to developing new solutions for sufferers.ADNFCR-8000103-ID-801607406-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.